EUCTR2010-024023-25-ES进行中（未招募）不适用
An open label, parallel groups, phase III, clinical trial to assess the antiproteinuric effects of the vitamin D derivates in patients with chronic kidney disease and vitamin D insufficiency. - Nefrovid2010
orenzo Victor, PhD0 个研究点目标入组 174 人开始时间: 2011年7月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 174
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
An open label, parallel group, Phase III clinical study in patients with advanced prostate cancer suitable for hormonal manipulation to demonstrate the non-inferiority of a new three-month Novosis Goserelin 10.8 mg implant versus the reference product Zoladex® 10.8 mg and to show the comparability of the Novosis Goserelin 3.6 mg implant applied every 28 days for three months with the new three-month Novosis Goserelin 10.8 mg implantprostate cancer suitable for hormonal manipulationEUCTR2006-004587-30-HUOVOSIS AG60
进行中（未招募）
不适用
An open label, parallel group phase III clinical study in patients with prostate cancer to demonstrate the non-inferiority of a new Novosis Leuprorelin 10.72 mg implant versus the reference product TrenantoneEUCTR2008-001687-37-HUovosis AG
已完成
1 期
Evaluation of safety and efficacy of convalescent plasma in COVID-19 patientsCTRI/2020/04/024804International Stemcell Services Ltd24
进行中（未招募）
不适用
Open-label randomized, parallel group, phase III, multicenter trial comparing two different sequences of therapy (irinotecan/cetuximab followed by fluorouracil/leucovorin with oxaliplatin (FOLFOX-4) vs. FOLFOX-4 followed by irinotecan/cetuximab) in metastatic colorectal patients treated with fluorouracil/leucovorin with irinotecan (FOLFIRI)/bevacizumab as first line chemotherapy - COMETS [COlorectal Metastatic Two Sequences]Patients with histologically confirmed metastatic colorectal cancer progressed after a first line treatment containing FOLFIRI and BEV.MedDRA version: 9.1Level: LLTClassification code 10061045Term: Colon neoplasmEUCTR2007-006254-26-ITGISCAD
尚未招募
3 期
An open label, randomised, muliticentre Phase III Trial of Dasatnib (SPRYCEL®) vs standard dose Imatininb (400mg) in the treatment of subjects with newly diagnosed chronic phase Philadelphia chromosome positive chronic myeloid leukaemia (CML).Chronic Myeloid Leukemia10024324NL-OMON31003Bristol-Myers Squibb5